C-Reactive Protein and Interleukin-18 Levels in Relation to Coronary Heart Disease: Prospective Cohort Study from Busselton Western Australia

Heart Lung and Circulation

Volumn 17, Issue 2, 2008, Pages 90-95

  Hung, Joseph ^a   Knuiman, Matthew W ^b   Divitini, Mark L ^b   Langton, Paul E ^a   Chapman, Caroline L ^c   Beilby, John P ^b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

C reactive protein; Coronary heart disease; Inflammation; Interleukin 18; Prognosis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 18;

ADULT; AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; AGED; C-REACTIVE PROTEIN; CORONARY DISEASE; FEMALE; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; WESTERN AUSTRALIA;

EID: 40749094363     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2007.07.002     Document Type: Article

References (31)

1. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., Galllimore J.R., and Pepys M.B. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321 (2000) 199-204
2. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
3. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M.H., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith Jr. S.C., Taubert K., Tracy R.P., and Vinicor F. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
4. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., Lowe G.D.O., Pepys M.B., and Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
5. Levinson S.S., Miller J.J., and Elin R.J. Poor predictive value of high-sensitivity C-reactive protein indicates need for reassessment. Clin Chem 50 (2004) 1733-1735
6. Tracy R.P., and Kuller L.H. C-reactive protein, heart disease risk, and the popular media. Arch Intern Med 165 (2005) 2058-2060
7. Okamura H., Tsuji H., Kashiwamura S., Yoshimoto T., and Nakanishi K. Interleukin-18: a novel cytokine that augments both acquired and innate immunity. Adv Immunol 70 (1998) 281-312
8. Szmitko P.E., Wang C.-H., Weisel R.D., de Almeida J.R., Anderson T.J., and Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 108 (2003) 1917-1923
9. Mallat Z., Corbaz A., Scoazec A., Besnard S., Leseche G., Chvatchko Y., and Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104 (2001) 1598-1603
10. Blankenberg S., Luc G., Ducimetiere P., Arveiler D., Ferrieres J., Amouyel P., Evans A., Cambien F., Tiret L., and on behalf of the PRIME Study Group. Interleukin-18 and the risk of coronary heart disease in European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 108 (2003) 2453-2459
11. Boekholdt S.M., Peters R.J.G., Hack C.E., Day N.E., Luben R., Bingham S., Wareham N.J., Reitsma P.H., and Khaw K.-T. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: The EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 24 (2004) 1503-1508
12. Knuiman M.W., Vu H.T., and Bartholomew H.C. Multivariate risk estimation for coronary heart disease: the Busselton Health Study. Aust NZ J Public Health 22 (1998) 747-753
13. Knuiman M.W., Watts G.F., and Divitini M.L. Is sialic acid an independent risk factor for cardiovascular disease? A 17-year follow-up study in Busselton, Western Australia. Ann Epidemiol 14 (2004) 627-632
14. Knuiman M.W., Jamrozik K., Welborn T.A., Bulsara M.K., Divitini M.L., and Whittall D.E. Age and secular trends in risk factors for cardiovascular disease in Busselton. Aust J Public Health 19 (1995) 375-382
15. Welborn T.A., Cumpston G.N., and Cullen K.J. The prevalence of coronary heart disease and associated factors in an Australian rural community. Am J Epidemiol 89 (1969) 521-536
16. Chapman C.M.L., Beilby J.P., McQuillan B.M., Thompson P.L., and Hung J. Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke 35 (2004) 1619-1624
17. Hung J., McQuillan B.M., Chapman C.M.L., Thompson P.L., and Beilby J.P. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 25 (2005) 1268-1273
18. Holman C.D.J., Bass A.J., Rouse I.L., and Hiobbs M.S.T. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust NZ J Public Health 23 (1999) 453-459
19. Prentice R.L. A case-cohort design for epidemiologic-disease relationships in an assembled cohort. Biometrika 73 (1986) 1-11
20. Barlow W.E. Robust variance estimation for case-cohort design. Biometrics 50 (1994) 1064-1072
21. Ichikawa L, Barlow W. ROBPHREG Version 1.0.2: Survival analysis macro with robust variance. http://lib.stat.cmu.edu/general/robphreg. Center for Health Studies, Group Health Cooperative; Seattle, USA, March 1998.
22. Jamrozik K., and Hockey R. Trends in risk factors for vascular diseases in Australia. Med J Aust 150 (1989) 14-18
23. Pepe M.S., Janes H., Longton G., Leisenring W., and Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159 (2004) 882-890
24. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
25. Ridker P.M., and Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 109 (2004) 1955-1959
26. van der Meer I.M., de Maat M.P.M., Kiliaan A.J., van der Kuip D.A.M., Hofman A., and Witteman J.C.M. The value of C-reactive protein in cardiovascular risk prediction: The Rotterdam Study. Arch Intern Med 163 (2003) 1323-1328
27. Wilson P.W.F., Nam B.-H., Pencina M., D'Agostino R.B.S., Benjamin E.J., and O'Donnell C.J. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 165 (2005) 2473-2478
28. Miller M., Zhan M., and Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: The Third National Health and Nutrition Examination Survey. Arch Intern Med 165 (2005) 2063-2068
29. Yamagami H., Kitagawa K., Hoshi T., Furukado S., Hougaku H., Nagai Y., and Hori M. Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol 25 (2005) 1458-1462
30. Chapman C.M.L., McQuillan B.M., Beilby J.P., Thompson P.L., and Hung J. Interleukin-18 levels are not associated with subclinical carotid atherosclerosis in a community population: The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Atherosclerosis 189 (2006) 414-419
31. Tiret L., Godefroy T., Lubos E., Nicaud V., Tregouet D.-A., Barbaux S., Schnabel R., Bickel C., Espinola-Klein C., Poirier O., Perret C., Munzel T., Rupprecht H.-J., Lackner K., Cambien F., Blankenberg S., and for the AtheroGene Investigators. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 112 (2005) 643-650